{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:58:50Z","timestamp":1781636330188,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zhaoyang Talent Special Project from Guangdong Provincial Hospital of Chinese Medicine","award":["ZY2022YL15"],"award-info":[{"award-number":["ZY2022YL15"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endometrial cancer significantly impacts women\u2019s reproductive health and quality of life, with lymph node metastasis serving as a crucial prognostic factor. Given the low metastasis rate, not all early-stage patients require lymph node dissection. The NCCN upgraded Sentinel Lymph Node Biopsy (SLNB) technology to Class 2A evidence. However, the applicability of SLNB for Chinese patients remains uncertain. This study evaluates the efficacy and safety of SLNB in a Chinese population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A retrospective cohort study was conducted at Guangdong Provincial Hospital of Chinese Medicine from August 2019 to December 2022, involving 166 early-stage endometrial adenocarcinoma patients. Of these, 137 patients were assessed as moderate to high-differentiated endometrioid adenocarcinoma. Patients were divided into Sentinel Lymph Node Biopsy (SLNB,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200943) and systematic lymph node dissection (SLND,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200994) groups, with a median follow-up time of 39 (24, 55) months. Primary outcomes were postoperative disease progression-free survival and one-month complication rates, with secondary endpoints including surgical parameters and quality of life indicators.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>\n                      During the follow-up(median follow-up time 39\u00a0months), 1 recurrence occurred in the SLNB group, with no recurrences in the SLND group. Sentinel Lymph Node Biopsy (SLNB) showed no statistically significant differences compared with traditional Sentinel Lymph Node Dissection (SLND) in oncological assessment, with no significant variations in postoperative pathological staging (\u03b2\u2009=\u20090.80, 95%CI: -1.29 to 2.90,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.455), pathological grading (\u03b2\u2009=\u2009-0.115, 95%CI: -0.99 to 0.76,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.800), and additional treatment evaluation (\u03b2\u2009=\u2009-0.214, 95%CI: -1.52 to 1.09,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.749), with one recurrence in the SLNB group during follow-up. SLNB significantly improved surgical indicators: operation time reduced by 85.13\u00a0min (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), blood loss decreased by 44.82\u00a0ml (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), hospital stay shortened by 1.19\u00a0days (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.030), with significantly lower postoperative day 1 pain scores. At 6\u00a0h post-surgery, both groups showed significant BADL decline (\u03b2\u2009=\u2009-21.53, 95%CI: -25.7 to -17.4,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with less functional impairment in the SLNB group and significantly shorter urinary catheter placement time (\u03b2\u2009= +\u20091.24, 95%CI: 0.90 to 1.59,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Complication analysis revealed significantly higher rates of lymphatic reflux obstruction (\u03b2\u2009=\u200918.22, 95%CI: 17.38 to 19.05,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and intestinal obstruction (\u03b2\u2009=\u200918.17, 95%CI: 16.16 to 20.17,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) in the SLND group, suggesting a marked advantage of SLNB in complication management.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For early-stage endometrial cancer patients with moderate to high differentiation and lesions confined to the inner half of the myometrium, SLNB demonstrates safety and efficacy as a minimally invasive alternative, significantly improving surgical outcomes and patient prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15748-2","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:36:30Z","timestamp":1772012190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of SLNB in early endometrial adenocarcinoma in China: a retrospective cohort study based on inverse probability of treatment weighting"],"prefix":"10.1186","volume":"26","author":[{"given":"Lingjuan","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanmei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"3","key":"15748_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"15748_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ygyno.2021.01.036","volume":"161","author":"B Gu","year":"2021","unstructured":"Gu B, Shang X, Yan M, et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. Gynecol Oncol. 2021;161(2):573\u201380. https:\/\/doi.org\/10.1016\/j.ygyno.2021.01.036.","journal-title":"Gynecol Oncol"},{"issue":"10333","key":"15748_CR3","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","volume":"399","author":"EJ Crosbie","year":"2022","unstructured":"Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(22)00323-3.","journal-title":"Lancet"},{"issue":"3","key":"15748_CR4","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.ygyno.2012.02.021","volume":"125","author":"JN Barlin","year":"2012","unstructured":"Barlin JN, Khoury-Collado F, Kim CH, et al. The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol. 2012;125(3):531\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2012.02.021.","journal-title":"Gynecol Oncol"},{"issue":"23","key":"15748_CR5","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1093\/jnci\/djn397","volume":"100","author":"P Benedetti Panici","year":"2008","unstructured":"Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707\u201316. https:\/\/doi.org\/10.1093\/jnci\/djn397.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"15748_CR6","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ygyno.2023.02.015","volume":"169","author":"VA Capozzi","year":"2023","unstructured":"Capozzi VA, et al. Long-term survival outcomes in high-risk endometrial cancer after SLN vs LND. Gynecol Oncol. 2023;169(3):456\u201363. https:\/\/doi.org\/10.1016\/j.ygyno.2023.02.015.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"15748_CR7","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1245\/s10434-023-14065-3","volume":"31","author":"G Bogani","year":"2024","unstructured":"Bogani G, Ditto A, Rossi EC, et al. Sentinel node mapping in early-stage endometrial cancer. Ann Surg Oncol. 2024;31(2):789\u201397. https:\/\/doi.org\/10.1245\/s10434-023-14065-3.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"15748_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3390\/jpm13020170","volume":"13","author":"IC Quevedo","year":"2023","unstructured":"Quevedo IC, Rodriguez-Aizcorbe Y, Barreto MA, et al. Personalized sentinel node mapping in endometrial cancer. J Pers Med. 2023;13(2):170. https:\/\/doi.org\/10.3390\/jpm13020170.","journal-title":"J Pers Med"},{"issue":"2","key":"15748_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ygyno.2023.01.010","volume":"168","author":"SK Agrawal","year":"2023","unstructured":"Agrawal SK, Reilly KA, Bakkum-Gamez JN, et al. Diagnostic performance of indocyanine green for SLN detection. Gynecol Oncol. 2023;168(2):345\u201352. https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.010.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"15748_CR10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/jso.26694","volume":"127","author":"S Xiong","year":"2023","unstructured":"Xiong S, Liu Y, Zhang L, et al. Meta-analysis of tracers in sentinel lymph node mapping. J Surg Oncol. 2023;127(4):456\u201365. https:\/\/doi.org\/10.1002\/jso.26694.","journal-title":"J Surg Oncol"},{"issue":"11","key":"15748_CR11","doi-asserted-by":"publisher","first-page":"6789","DOI":"10.1245\/s10434-023-14070-6","volume":"30","author":"C Nahmias","year":"2023","unstructured":"Nahmias C, Smith J, Martin E, et al. National implementation and accuracy of SLN biopsy. Ann Surg Oncol. 2023;30(11):6789\u201398. https:\/\/doi.org\/10.1245\/s10434-023-14070-6.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"15748_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ygyno.2022.01.015","volume":"166","author":"YN Kim","year":"2022","unstructured":"Kim YN, Park JY, Lee SH, et al. Sentinel lymph node biopsy in high-risk endometrial cancer. Gynecol Oncol. 2022;166(1):89\u201396. https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.015.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"15748_CR13","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.3802\/jgo.2022.33.e73","volume":"33","author":"JY Park","year":"2022","unstructured":"Park JY, Kim YN, Lee SH, et al. Randomized comparisons of SLN biopsy. J Gynecol Oncol. 2022;33(4):e73. https:\/\/doi.org\/10.3802\/jgo.2022.33.e73.","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"15748_CR14","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/jso.26694","volume":"125","author":"Y Xue","year":"2022","unstructured":"Xue Y, Liu Z, Wang L, et al. Efficacy of sentinel lymph node mapping in endometrial cancer. J Surg Oncol. 2022;125(3):256\u201363. https:\/\/doi.org\/10.1002\/jso.26694.","journal-title":"J Surg Oncol"},{"issue":"1","key":"15748_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/ijgo.14307","volume":"160","author":"A Dick","year":"2023","unstructured":"Dick A, Smith J, Johnson K, et al. Sentinel lymph node mapping guidelines comparison. Int J Gynaecol Obstet. 2023;160(1):220\u20135. https:\/\/doi.org\/10.1002\/ijgo.14307.","journal-title":"Int J Gynaecol Obstet"},{"issue":"21","key":"15748_CR16","doi-asserted-by":"publisher","first-page":"6462","DOI":"10.3390\/jcm11216462","volume":"11","author":"WK Chiu","year":"2022","unstructured":"Chiu WK, Lee CK, Wong RKC, et al. Applications and safety of sentinel lymph node biopsy. J Clin Med. 2022;11(21):6462. https:\/\/doi.org\/10.3390\/jcm11216462.","journal-title":"J Clin Med"},{"key":"15748_CR17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ygyno.2022.11.003","volume":"168","author":"B Cormier","year":"2023","unstructured":"Cormier B, Rossi EC, Bixel K, et al. Aortic sentinel lymph nodes in endometrial cancer: a prospective study. Gynecol Oncol. 2023;168:45\u201351. https:\/\/doi.org\/10.1016\/j.ygyno.2022.11.003.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"15748_CR18","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1097\/AOG.0000000000004254","volume":"137","author":"LA Meyer","year":"2021","unstructured":"Meyer LA, Lasala J, Broaddus RR, et al. Enhanced recovery pathways in minimally invasive gynecologic surgery. Obstet Gynecol. 2021;137(2):338\u201348. https:\/\/doi.org\/10.1097\/AOG.0000000000004254.","journal-title":"Obstet Gynecol"},{"issue":"11","key":"15748_CR19","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1245\/s10434-020-08533-9","volume":"27","author":"F Ghezzi","year":"2020","unstructured":"Ghezzi F, Bogani G, Casarin J, et al. Lymphatic sequelae after lymphadenectomy. Ann Surg Oncol. 2020;27(11):4184\u201392. https:\/\/doi.org\/10.1245\/s10434-020-08533-9.","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"15748_CR20","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S1470-2045(17)30068-2","volume":"18","author":"EC Rossi","year":"2017","unstructured":"Rossi EC, Kowalski LD, Scalici J, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017;18(3):384\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(17)30068-2.","journal-title":"Lancet Oncol"},{"issue":"5","key":"15748_CR21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1136\/ijgc-2023-004472","volume":"33","author":"R Kahn","year":"2023","unstructured":"Kahn R, Leitao MM. Mapping the landscape of sentinel lymph nodes in endometrial cancer: let us continue in the right direction. Int J Gynecol Cancer. 2023;33(5):860\u20131. https:\/\/doi.org\/10.1136\/ijgc-2023-004472.","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"15748_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ygyno.2023.03.020","volume":"169","author":"Sentirec-endo Study Group","year":"2023","unstructured":"Sentirec-endo Study Group. National adoption of SLN mapping. Gynecol Oncol. 2023;169(2):345\u201353. https:\/\/doi.org\/10.1016\/j.ygyno.2023.03.020.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"15748_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ygyno.2020.05.007","volume":"158","author":"G Bogani","year":"2020","unstructured":"Bogani G, Lopez S, Urraro F, et al. Propensity-matched analyses of survival outcomes. Gynecol Oncol. 2020;158(1):77\u201383. https:\/\/doi.org\/10.1016\/j.ygyno.2020.05.007.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"15748_CR24","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.3390\/jcm12062241","volume":"12","author":"V Di Donato","year":"2023","unstructured":"Di Donato V, Palaia I, Pauselli S, et al. Recent advances in endometrial cancer management. J Clin Med. 2023;12(6):2241. https:\/\/doi.org\/10.3390\/jcm12062241.","journal-title":"J Clin Med"},{"key":"15748_CR25","doi-asserted-by":"publisher","first-page":"1306343","DOI":"10.3389\/fmed.2023.1306343","volume":"10","author":"J Shi","year":"2023","unstructured":"Shi J, Li J, Zhang Y, et al. Progress and prospect of sentinel lymph node mapping. Front Med. 2023;10:1306343. https:\/\/doi.org\/10.3389\/fmed.2023.1306343.","journal-title":"Front Med"},{"issue":"17","key":"15748_CR26","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.3390\/cancers16173107","volume":"16","author":"J Laufer","year":"2024","unstructured":"Laufer J, Goldman DA, Aghajanian C, et al. Impact of indocyanine green dose on sentinel lymph node mapping. Cancers. 2024;16(17):3107. https:\/\/doi.org\/10.3390\/cancers16173107.","journal-title":"Cancers"},{"issue":"1","key":"15748_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/ijgc-2023-004500","volume":"34","author":"ALICE\/ALIEN Trial Publications","year":"2024","unstructured":"ALICE\/ALIEN Trial Publications. Int J Gynecol Cancer. 2024;34(1):45\u201353. https:\/\/doi.org\/10.1136\/ijgc-2023-004500.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"15748_CR28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/ijgc-2022-004014","volume":"33","author":"A Raffone","year":"2023","unstructured":"Raffone A, Fanfani F, Raimondo D, et al. Predictive factors of sentinel lymph node failed mapping in endometrial carcinoma patients: a systematic review and meta-analysis. Int J Gynecol Cancer. 2023;33(6):853\u20139. https:\/\/doi.org\/10.1136\/ijgc-2022-004014.","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"15748_CR29","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.3802\/jgo.2024.35.e29","volume":"35","author":"J Casarin","year":"2024","unstructured":"Casarin J, Atassi A, Bizzarri N, et al. Sentinel lymph node mapping techniques. J Gynecol Oncol. 2024;35(1):e29. https:\/\/doi.org\/10.3802\/jgo.2024.35.e29.","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"15748_CR30","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/ijgc-2023-004600","volume":"34","author":"J Mauro","year":"2024","unstructured":"Mauro J, Patel H, Rodriguez A, et al. Assessment of sentinel lymp\u3002h node mapping. Int J Gynecol Cancer. 2024;34(2):156\u201365. https:\/\/doi.org\/10.1136\/ijgc-2023-004600.","journal-title":"Int J Gynecol Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15748-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15748-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15748-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:51:17Z","timestamp":1781635877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15748-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15748"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15748-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4832100\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"31 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (Approval Reference: ZE2024-144\u201301; Date: April 30, 2024). All procedures were conducted in accordance with the ethical standards of the Declaration of Helsinki and relevant Chinese guidelines for biomedical research involving human participants. Given the retrospective nature of this study, the requirement for written informed consent was waived by the ethics committee, and all patient data were anonymized prior to analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"425"}}